https://www.selleckchem.com/pr....oducts/fen1-in-4.htm
gulators, and industry representatives to discuss trial design and conduct including alternative designs, eligibility criteria, instruments for patient- and observer-reported outcomes, and optimal primary endpoints to support regulatory approval. This report summarizes the workshop, key challenges and knowledge gaps identified, and outlines areas where further research efforts are needed to overcome barriers to developing drugs to treat these conditions. To evaluate the safety and use of the 3D-Transit system (Motilis SA, Lausanne, Sw
Like
Comment
Share
